MUBII-TB-DB: a database of mutations associated with antibiotic resistance in Mycobacterium tuberculosis
© Flandrois et al.; licensee BioMed Central Ltd. 2014
Received: 9 December 2013
Accepted: 7 April 2014
Published: 14 April 2014
Tuberculosis is an infectious bacterial disease caused by Mycobacterium tuberculosis. It remains a major health threat, killing over one million people every year worldwide. An early antibiotic therapy is the basis of the treatment, and the emergence and spread of multidrug and extensively drug-resistant mutant strains raise significant challenges. As these bacteria grow very slowly, drug resistance mutations are currently detected using molecular biology techniques. Resistance mutations are identified by sequencing the resistance-linked genes followed by a comparison with the literature data. The only online database is the TB Drug Resistance Mutation database (TBDReaM database); however, it requires mutation detection before use, and its interrogation is complex due to its loose syntax and grammar.
The MUBII-TB-DB database is a simple, highly structured text-based database that contains a set of Mycobacterium tuberculosis mutations (DNA and proteins) occurring at seven loci: rpoB, pncA, katG; mabA(fabG1)-inhA, gyrA, gyrB, and rrs. Resistance mutation data were extracted after the systematic review of MEDLINE referenced publications before March 2013. MUBII analyzes the query sequence obtained by PCR-sequencing using two parallel strategies: i) a BLAST search against a set of previously reconstructed mutated sequences and ii) the alignment of the query sequences (DNA and its protein translation) with the wild-type sequences. The post-treatment includes the extraction of the aligned sequences together with their descriptors (position and nature of mutations). The whole procedure is performed using the internet. The results are graphs (alignments) and text (description of the mutation, therapeutic significance). The system is quick and easy to use, even for technicians without bioinformatics training.
MUBII-TB-DB is a structured database of the mutations occurring at seven loci of major therapeutic value in tuberculosis management. Moreover, the system provides interpretation of the mutations in biological and therapeutic terms and can evolve by the addition of newly described mutations. Its goal is to provide easy and comprehensive access through a client–server model over the Web to an up-to-date database of mutations that lead to the resistance of M. tuberculosis to antibiotics.
KeywordsTuberculosis Antibiotics Mutation database Sequence database Web
Tuberculosis (TB) is an infectious disease caused by a slow-growing bacterium, Mycobacterium tuberculosis, which has been linked to humans since the beginning of the early human expansion from east Africa . Tuberculosis was the main cause of deaths in Western Europe between the seventeenth century and the end of the nineteenth century . It remains a major health threat, killing more than a million individuals every year worldwide. Although the WHO claims that its goal to halt and reverse the TB epidemic by 2015 has already been achieved and that the TB mortality rate has decreased by 41% since 1990, the global burden of TB remains. In 2011, there were an estimated 8.7 million new cases of TB, and 1.4 million people died from TB.
No fully effective vaccination is possible because the Bacille de Calmette et Guérin (BCG)-vaccine protection against TB varies among populations  and provides only limited protection during childhood . The limitation of the TB expansion is thus based on the improvement and generalization of diagnostic methods  and early antibiotic therapy. The WHO recommends the following combined therapy employing first-line antibiotics: rifampicin (or rifabutin), isoniazid, pyrazinamide and ethambutol for two months followed by rifampicin and isoniazid for four months .
However, irregular and low-dose treatment has led to the emergence and spread of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Mycobacterium tuberculosis complex (MTBC) strains that present significant challenges in disease control [6–8]. The resistance increases in high MDR-TB burden countries, where the number of cases was estimated to be 60,000 worldwide in 2011. In these countries, the proportion of resistant strains varies from 5 to 19% of new TB cases and up to 50% for retreatment cases. This increase in resistance has led to the promotion of laboratory antimicrobial testing for all isolates . In the case of antibiotic resistance, the therapy is conducted using second-line drugs, such as aminoglycosides or non-conventional antibiotics (such as fluoroquinolones).
The traditional phenotypic drug susceptibility test induces serious delays in the detection of resistance due to the extremely slow growth of M. tuberculosis, the answer being obtained in most cases two weeks after the isolation of the bacteria. Another drawback of the in vitro susceptibility testing is the inadequate detection of resistance to new drugs and to pyrazinamide [9–11]. The rapid diagnosis of drug resistance by molecular methods is essential to initiate effective antibiotic therapies and to prevent the transmission of drug-resistant strains .
M. tuberculosis acquires drug resistance primarily through mutations in specific genes [13, 14]. The mutations associated with drug resistance occur in rpoB for rifampicin (RIF), in katG and the mabA (fabG1)-inhA operon for isoniazid (INH), in pncA for pyrazinamide (PZA), in rrs for amikacin (AMK) and in gyrA and gyrB for fluoroquinolones (FQs) [13, 15–17].
Several commercial molecular kits are available to detect M. tuberculosis resistance using line-probe assays or real-time PCR, and these kits allow for the prediction of drug resistance in clinical specimens within one working day . They can detect the mutations responsible for resistance to RIF alone (GeneXpert MTB/RIF (Cepheid), INNO-LiPA® Rif. TB (Innogenetics)), to RIF + INH (GenoType® MTBDRplus (Hain LifeScience GmbH)), or to FQs + AMK (GenoType® MTBDRsl (Hain LifeScience GmbH)), but their sensitivity varies, depending on the antibiotic . These kits, unfortunately, detect only the most frequent mutations [18, 19]. An alternative approach that allows for the exhaustive detection of mutations consists of the PCR amplification and sequencing of resistance-linked genes [20, 21] and, more experimentally, of complete genome sequencing . It is, however, time consuming to compare the sequences with the reference genome and the mutation identity with the literature data. Recently, Sandgren et al.  established a comprehensive database that gathers information on the mutations associated with TB drug resistance and the frequency of the most common mutations associated with resistance to specific drugs. The TBDReaM database is a free online resource that allows for the molecular diagnosis of resistant TB after the processing of the amplified sequences by any method. Although very helpful, the TBDReaM database has not been updated since April 2010, and its usage remains time consuming because it demands prior processing of the TB nucleotide sequences to detect mutations and cannot be easily interrogated due to its relaxed grammatical conception.
Here, we describe MUBII-TB-DB, a database of the mutations of M. tuberculosis linked to resistance to first-line and second-line antibiotics that can be used to identify the mutations from a submitted sequence. This database and its related software, MUBII, have been developed to satisfy the need of clinical microbiology labs to easily analyze M. tuberculosis sequences and to link the results to a potential therapeutic failure. MUBII combines the use of reconstructed mutated gene sequences that can be searched by BLAST, aligned against the wild-type gene sequence, and compared with the mutation database. This concept can be easily adapted to the microbiological identification of other microbial mutations.
Construction and contents
The database was constructed based on a systematic review of the literature, as described below. We focused on publications reporting an association between specific mutations in clinical isolates of M. tuberculosis and phenotypic resistance to INH, RIF, PZA, FQs, and AMK. The genes studied were rpoB for RIF; inhA, katG, and the promoter region of the mabA(FabG1)-inhA operon for INH; pncA for PZA; gyrA and gyrB for FQs; and rrs for AMK. As a starting point, we used the TBDReaM database because it constitutes a comprehensive resource on drug resistance mutations in M. tuberculosis based on studies published from January 1966 to December 2009 . Additional publications on M. tuberculosis resistance mutations recorded in MEDLINE from December 2009 to March 2013 were included in the analysis (see infra). All publications reporting mutations, including the ones recorded in the TBDReaM database, were carefully reviewed for the consistency of the information about the mutated nucleotide and amino acid. We used the codon numbering given by the annotation of the M. tuberculosis whole genome sequence published in .
Strategy of the systematic literature review
All studies reporting an association between specific mutations in clinical isolates of M. tuberculosis and phenotypic resistance to INH, RIF, PZA, FQs and AMK that were previously selected for the construction of the TBDReaM database have been included again in our survey. Moreover, we searched the MEDLINE database for similar works issued since the TBDReaM database release (Dec 2009 – Mar 2013). We also searched for additional references in the bibliographies of the reports and reviews. Only English language articles were considered. Combinations of the following search terms were used:
Tuberculosis AND (mutation OR mutations) AND (isoniazid OR rifampin OR fluoroquinolones OR amikacin OR pyrazinamide OR katg OR maba OR fabg1 OR inha OR rpob OR rrs OR pnca OR gyra OR gyrb).
A study was included in the database under the following conditions: 1) it was a survey of clinical M. tuberculosis isolates; 2) drug sensitivity testing was performed on all isolates tested for mutations; and 3) the nucleotide or codon position and the nucleotide or amino acid change were given.
Mutations with therapeutic relevance are tagged as “high-confidence” mutations in the MUBII-TB-DB database. High-confidence mutations have been previously defined by Sandgren et al.  as mutations associated with in vitro documented resistance reported by at least 10 publications based on the analysis of different sets of strains.
List of the reference gene sequences of Mycobacterium tuberculosis
[AL123456] REGION: 759808 to 763325
pncA (including the promoter)
[AL123456] REGION: 2288681 to 2289280
[AL123456] REGION: 1673325 to 1673439
[AL123456] REGION: 1674202 to 1675011
[AL123456] REGION: 2153889 to 2156111 identical to [×68081.1]
[AL123456] REGION: 7302 to 9818
[AL123456] REGION: 5123 to 7267
[AL123456] REGION: 1471846 to 1473762 identical to [NR_102810]
For each gene, there is a corresponding separate subset of the database, a text file with the description of a given mutation on each line. The line contains both the descriptions of the mutation (nucleotides and amino acids, if applicable), notes on the mutation (for instance, therapeutic relevance) and rules to apply.
Example of a mutation database: a part of the rpo B mutation database for Mycobacterium tuberculosis
A1291G ~ S431G ~ ~
Nucleotide chain: A at position 1291 is replaced by G; Protein chain: S at position 431 is replaced by G
+1300TTC ~ +434 F ~ ~
Insertion of TTC at position 1300 (F at position 434 of the protein)
CAG1306- ~ Q436- ~ ~
Deletion of CAG at position 1306 (deletion of Q at position 436 of the protein)
C1331T ~ T4441 ~ High Confidence ~ See mutDB2012
Example with a note and a remark
C1294T ~ Q432- ~ Rare ~ RULE::STOPCODON
Example with a note and a rule
CATGGACCAGAA1299- ~ MDQN434- ~ ~RULE::AMBIGUOUS= > N_ATGGACCAGAAC1300-
Example of a deletion occurring within a repeated zone. The position 1299 deduced from the nucleotide-level sequence alignment is corrected in the results
wildNPmutatedN ~ wildXPmutatedX[~Notes[~RULE::type[,action][~Remarks]]]/~Remarks]
where P is the position on the nucleotide or protein chain; N is a nucleotide (or short sequence); and X is an amino-acid or a short peptide sequence. Notes are written freely and may contain alphanumeric characters and punctuation, except the tilde sign. The specific tag “Rules::” identifies the actions to apply to clearly differentiate the rules from the remarks. Rules modify the computed result, for example, to suppress the peptide sequence if a stop codon is created or to correct the result in the case of ambiguous positions of indels that occur within repeated features. Remarks are not used by the programs but are information, such as references and dates, linked to the database entry.
Other data are also recorded in the database: the position of the first codon of the nucleotide chain, the status of the final main product (DNA/protein), and the DNA sequence of the wild strain (the reference sequence). Therefore, each gene-mutation database is a series of flat files containing the descriptions of the mutations and a series of files containing the character sequences in FASTA format as well as the locations of the final gene products and non-coding zones.
The Web interface exclusively uses CGI and HTML. Cascading Style Sheets are used to color the alignments. These decisions were made to achieve simplicity and reliability on every browser. The Web server runs under the APACHE MPM Prefork http server on a LINUX Debian server.
De novoconstructed BLASTN database
Only a few mutated sequences are available in GenBank; therefore, the construction of a database containing the sequences of all the described mutations is necessary. A sequence database is built containing a unique mutation event for each of the sequences. It contains the descriptions of the mutations present in MUBII-TB-DB, the reference sequence and the position of the promoter if required. The mutated sequences are written in the FASTA format at the nucleotide level with the description of the mutation as the descriptor. This database is rebuilt when changes occur within MUBII-TB-DB and is compiled as a BLAST database.
DNA sequence analysis
The query sequence for a given gene is submitted in the FASTA format to the program through an HTML interface. A preliminary nucleotide BLAST2seq against the gene reference sequence is used to test if the query is given as a + direct string and, if not, computes its complementary strand. BLAST2seq does not allow for the identification of mutations that may occur in the extremities of the sequence.
Alignment to the reference and extraction of the core of the aligned sequences
The query sequence is aligned to the reference sequence by MAFFT. An algorithm identifies the core of the alignment by eliminating the trailing short sequences that are not perfectly aligned at the extremities. The core of the alignment is further used for mutation detection.
The alignment was initially produced using MUSCLE, but as the program tries to align the whole length of the reference sequence to a query that is often a partial sequence, the ends of the query were frequently assigned to positions near the ends of the reference. This problem was observed especially in the low quality-extremities of the query and has been found to occur less frequently when using MAFFT.
Extraction of the mutations from the alignment and identification
For the core section of the alignment, a program extracts the non-matching sections and constructs a Python dictionary of the results. Each entry of this dictionary is compared with the entries of a mutation dictionary for the given gene constructed from the MUBII-TB-DB database. The resulting table contains a description of each point mutation, insertion or deletion and indicates its presence or absence in the database. In the case of deletion or insertion, the possibility of frameshift creation is also checked, and the result is added in an “alert” section. Moreover, if the mutation is known and modifies the encoded protein, this information is included. In the case of mutations usually identified by their positions in the Escherichia coli gene (some sections of the rpoB gene), the E. coli gene position is also computed. Finally, if the identified mutation requires interpretation, the result is corrected to fulfill the RULE:: indications. All results are saved in files in a format ready for inclusion in the HTML page.
BLASTN on a reconstructed mutated sequence database
A BLASTN of the query against the constructed mutated sequence database is performed, and the descriptors of the best matching sequences are added to the results. The whole BLASTN result is also saved.
DNA translation to protein
The protein translation of the core of the nucleotide alignment is obtained using transeq from the EMBOSS library.
Output page construction
An HTML output file is computed for the whole alignment (DNA and protein levels) that highlights mutations using colored tags. The information gathered in the various results files is returned (detected mutations and frameshifts, mutation identification, BLAST result on the reconstructed sequence database, position within the M. tuberculosis wild-type gene, and, if possible, position within the E. coli gene). The results, alerts and alignment are placed in iframes that enable horizontal browsing and searching to inspect sequences for mutations. A specific output adapted for printing is constructed. It provides information about the detected mutations along with alignments using the showalign EMBOSS routine.
We have used the in silico mutation generation routine of MUBII to generate a mutated version of the M. tuberculosis H37Rv sequence. For every gene and every mutation described in MUBII-TB-DB, we have constructed a sequence containing the required modification (e.g., base change, deletion, insertion). The mutated sequence thus obtained was then submitted to MUBII to verify the accuracy of the answer. All described mutations as well as hundreds of random mutations have been checked, and the MUBII results have been carefully analyzed. This procedure has identified uncertainties in mutation identification when an indel occurs near or within repeated features, especially in the rpoB gene. An interpretation RULE has been added to indicate such a situation and modify the answer accordingly. Following this extended quality control, both the MUBII-TB-DB database and the MUBII process have been validated for use.
Utility and discussion
The use of MUBII is straightforward, as the submission of the FASTA formatted sequence and the name of the corresponding gene are performed using a standard Web browser. It is also possible to use a test sequence for demonstration purposes or to verify the system.
Utility and discussion
The MUBII algorithm and the MUBII-TB-DB resistance database have been tested using amplified sequences from MTBC strains isolated in our laboratory since January 2010 (approximately 350 strains, including 30 TB-MDR strains from our collection). No mutation was detected in the MTBC strains that were classified as susceptible to the antibiotics using the in vitro susceptibility test. The mutations detected in the TB-MDR strains were fully concordant with the mutations identified in the French National Reference Centre for Mycobacteriology (National Microbiology Laboratory, Hôpital de la Pitié-Salpétrière, Paris, France). MUBII-TB-DB has been used routinely by 12 molecular biology laboratory technicians and 6 microbiologists in the Mycobacteria laboratory of the University hospital in Lyon, France for eight months. The laboratory technicians were trained to work with websites and a laboratory information management system. A very short demonstration of the use of the website was provided to each laboratory technician through the analysis of real samples. The website has been unanimously judged as user-friendly, especially because of the direct indication of mutations and the printed results that are included in the patient's record. The microbiologists who tested MUBII-TB-DB preferred its output over the previous time-consuming method combining blast2seq (at the DNA and protein levels) with searches in a local database (both electronic and paper) and/or TBDReaM database.
The growing incidence and spread of antibiotic-resistant M. tuberculosis has led to efforts to identify the mutations in clinical isolates. The mutations linked to therapy failure are a particularly serious concern for physicians managing TB patients. The reference method is to sequence the gene of interest and then to detect and identify possible mutations. This process is time consuming, as there is no mutation database directly coupled to an analysis tool that allows for the submission of a sequence, its comparison to the database and the immediate analysis of the results. MUBII-TB-DB is a structured database collecting the description and information on modifications to seven loci of major therapeutic value in tuberculosis. The simple structure and grammar of MUBII-TB-DB contribute to the evolving capacity of the database, which can be easily updated with new entries (both mutations and resistance genes). MUBII-TB-DB is adapted to MUBII, a query and interpretation engine that is interrogated via a website. The sequence of a gene implicated in TB antibiotic resistance is analyzed simultaneously as a DNA string by BLAST against a de novo constructed sequence database and by an alignment process for the DNA and protein sequences. The results are graphs (alignments) and text (description of the mutation, previous description, therapeutic signification). MUBII-TB-DB is fast and easy to use, even by technicians without bioinformatics training. The system provides access to an interpretation in biological and therapeutic terms. It enables the automation of repetitive and somewhat technically challenging tasks in the tuberculosis laboratory. Its interest is to provide easy and comprehensive access to an up-to-date antibiotic resistance database concerning M. tuberculosis. Moreover, our algorithm is applicable to any mutation database and to any microorganism, making MUBII a useful tool for the surveillance and control of multidrug-resistant microorganisms.
The database is available at http://umr5558-bibiserv.univ-lyon1.fr/mubii/mubii-select.cgi.
World Health Organization
Extensively Drug Resistant
The vaccine using the attenuated “Bacille de Calmette et Guérin”
Mycobacterium tuberculosis complex
We thank Manolo Gouy for useful discussions during the elaboration of the manuscript.
- Comas I, Coscolla M, Luo T, Borrell S, Holt KE, Kato-Maeda M, Parkhill J, Malla B, Berg S, Thwaites G, Yeboah-Manu D, Bothamley G, Mei J, Wei L, Bentley S, Harris SR, Niemann S, Diel R, Aseffa A, Gao Q, Young D, Gagneux S: Out-of-Africa migration and Neolithic coexpansion of Mycobacterium tuberculosis with modern humans. Nat Genet. 2013, 45 (10): 1176-1182. 10.1038/ng.2744.View ArticlePubMed CentralPubMedGoogle Scholar
- Wilson LG: Commentary: Medicine, population, and tuberculosis. Int J Epidemiol. 2005, 34: 521-524.View ArticlePubMedGoogle Scholar
- Abubakar I, Pimpin L, Ariti C, Beynon R, Mangtani P, Sterne J, Fine P, Smith P, Lipman M, Elliman D, Watson J, Drumright L, Whiting P, Vynnycky E, Rodrigues L: Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guérin vaccination against tuberculosis. Health Technol Assess. 2013, 17: 1-372.View ArticlePubMedGoogle Scholar
- Colditz GA: Efficacy of BCG Vaccine in the Prevention of Tuberculosis Meta-analysis of the Published Literature. JAMA. 1994, 271: 698-10.1001/jama.1994.03510330076038.View ArticlePubMedGoogle Scholar
- Boehme CC, Saacks S, O’Brien RJ: The changing landscape of diagnostic services for tuberculosis. Semin Respir Crit Care Med. 2013, 34: 17-31. 10.1055/s-0032-1333468.View ArticlePubMedGoogle Scholar
- World Health Organization: WHO Global tuberculosis report 2012. 2012, Geneva, Switzerland: Word Health OrganizationGoogle Scholar
- Sotgiu G, Centis R, D’Ambrosio L, Tadolini M, Castiglia P, Migliori GB: Do we need a new Fleming époque: The nightmare of drug-resistant tuberculosis. Int J Mycobacteriology. 2013, 2: 123-125. 10.1016/j.ijmyco.2013.07.001.View ArticleGoogle Scholar
- Lynch JB: Multidrug-resistant Tuberculosis. Med Clin North Am. 2013, 97 (4): 553-579. 10.1016/j.mcna.2013.03.012. ix–xView ArticlePubMedGoogle Scholar
- Wilson ML: Rapid diagnosis of Mycobacterium tuberculosis infection and drug susceptibility testing. Arch Pathol Lab Med. 2013, 137: 812-819. 10.5858/arpa.2011-0578-RA.View ArticlePubMedGoogle Scholar
- Horne DJ, Pinto LM, Arentz M, Lin S-YG, Desmond E, Flores LL, Steingart KR, Minion J: Diagnostic accuracy and reproducibility of WHO-endorsed phenotypic drug susceptibility testing methods for first-line and second-line antituberculosis drugs. J Clin Microbiol. 2013, 51: 393-401. 10.1128/JCM.02724-12.View ArticlePubMed CentralPubMedGoogle Scholar
- Piersimoni C, Mustazzolu A, Giannoni F, Bornigia S, Gherardi G, Fattorini L: Prevention of false resistance results obtained in testing the susceptibility of Mycobacterium tuberculosis to pyrazinamide with the Bactec MGIT 960 system using a reduced inoculum. J Clin Microbiol. 2013, 51: 291-294. 10.1128/JCM.01838-12.View ArticlePubMed CentralPubMedGoogle Scholar
- Falzon D, Jaramillo E, Schünemann HJ, Arentz M, Bauer M, Bayona J, Blanc L, Caminero JA, Daley CL, Duncombe C, Fitzpatrick C, Gebhard A, Getahun H, Henkens M, Holtz TH, Keravec J, Keshavjee S, Khan AJ, Kulier R, Leimane V, Lienhardt C, Lu C, Mariandyshev A, Migliori GB, Mirzayev F, Mitnick CD, Nunn P, Nwagboniwe G, Oxlade O, Palmero D, et al: WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J. 2011, 38: 516-528. 10.1183/09031936.00073611.View ArticlePubMedGoogle Scholar
- Heym B, Cole ST: Multidrug resistance in Mycobacterium. Int J Antimicrob Agents. 1997, 8: 61-70. 10.1016/S0924-8579(96)00356-1.View ArticlePubMedGoogle Scholar
- Warner DF, Mizrahi V: Complex genetics of drug resistance in Mycobacterium tuberculosis. Nat Genet. 2013, 45: 1107-1108. 10.1038/ng.2769.View ArticlePubMedGoogle Scholar
- Musser JM: Antimicrobial agent resistance in mycobacteria: molecular genetic insights . Antimicrobial Agent Resistance in Mycobacteria: Molecular Genetic Insights. Clin Microbiol. 1995, 8: 496-514.Google Scholar
- Almeida Da Silva PEA, Palomino JC: Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J Antimicrob Chemother. 2011, 66: 1417-1430. 10.1093/jac/dkr173.View ArticlePubMedGoogle Scholar
- Zhang Y, Yew WW: STATE OF THE ART Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 2009, 13: 1320-1330.PubMedGoogle Scholar
- Kontsevaya I, Ignatyeva O, Nikolayevskyy V, Balabanova Y, Kovalyov A, Kritsky A, Matskevich O, Drobniewski F: Diagnostic accuracy of the genotype MTBDRsl assay for rapid diagnosis of extensively drug-resistant tuberculosis in HIV-coinfected patients. J Clin Microbiol. 2013, 51: 243-248. 10.1128/JCM.02513-12.View ArticlePubMed CentralPubMedGoogle Scholar
- Alonso M, Palacios JJ, Herranz M, Penedo A, Menéndez A, Bouza E, García de Viedma D: Isolation of Mycobacterium tuberculosis strains with a silent mutation in rpoB leading to potential misassignment of resistance category. J Clin Microbiol. 2011, 49: 2688-2690. 10.1128/JCM.00659-11.View ArticlePubMed CentralPubMedGoogle Scholar
- Campbell PJ, Morlock GP, Sikes RD, Dalton TL, Metchock B, Starks AM, Hooks DP, Cowan LS, Plikaytis BB, Posey JE: Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2011, 55: 2032-2041. 10.1128/AAC.01550-10.View ArticlePubMed CentralPubMedGoogle Scholar
- Feuerriegel S, Oberhauser B, George AG, Dafae F, Richter E, Rüsch-Gerdes S, Niemann S: Sequence analysis for detection of first-line drug resistance in Mycobacterium tuberculosis strains from a high-incidence setting. BMC Microbiol. 2012, 12: 90-10.1186/1471-2180-12-90.View ArticlePubMed CentralPubMedGoogle Scholar
- Zhang H, Li D, Zhao L, Fleming J, Lin N, Wang T, Liu Z, Li C, Galwey N, Deng J, Zhou Y, Zhu Y, Gao Y, Wang T, Wang S, Huang Y, Wang M, Zhong Q, Zhou L, Chen T, Zhou J, Yang R, Zhu G, Hang H, Zhang J, Li F, Wan K, Wang J, Zhang X-E, Bi L: Genome sequencing of 161 Mycobacterium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistance. Nat Genet. 2013, 45: 1255-1260. 10.1038/ng.2735.View ArticlePubMedGoogle Scholar
- Sandgren A, Strong M, Muthukrishnan P, Weiner BK, Church GM, Murray MB: Tuberculosis drug resistance mutation database. PLoS Med. 2009, 6: e2-10.1371/journal.pmed.1000002.View ArticlePubMedGoogle Scholar
- Cole S, Brosch R, Parkhill J, Garnier T: Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. 1998, 393: 537-544. 10.1038/31159.View ArticlePubMedGoogle Scholar
- Tatusova TA, Madden TL: BLAST 2 Sequences, a new tool for comparing protein and nucleotide sequences. FEMS Microbiol Lett. 1999, 174: 247-250. 10.1111/j.1574-6968.1999.tb13575.x.View ArticlePubMedGoogle Scholar
- Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ: Basic local alignment search tool. J Mol Biol. 1990, 215: 403-410. 10.1016/S0022-2836(05)80360-2.View ArticlePubMedGoogle Scholar
- Edgar RC: MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 2004, 32: 1792-1797. 10.1093/nar/gkh340.View ArticlePubMed CentralPubMedGoogle Scholar
- Katoh K, Toh H: Recent developments in the MAFFT multiple sequence alignment program. Brief Bioinform. 2008, 9: 286-298. 10.1093/bib/bbn013.View ArticlePubMedGoogle Scholar
- Rice P, Longden I, Bleasby A: EMBOSS: The European Molecular Biology Open Software Suite. Trends Genet. 2000, 16: 2-3.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.